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A B S T R A C T
The unique requirements of poorly water-soluble drug delivery have driven a great deal of research into new
formulations and routes of administration. This study investigates the use of nanosuspensions for solubility
enhancement and drug delivery. Simple methods were used to prepare nasal formulations of loratadine based on
nanosuspension pre-dispersion with sodium hyaluronate as a mucoadhesive agent. The nanosuspension was
prepared by antisolvent precipitation method followed by ultrasonication and characterized for particle size,
polydispersity index, zeta potential, morphology, and structure. Moreover, the nasal formulations were char-
acterized for drug loading, pH, particle size, viscosity, bioadhesive viscosity parameter, and were evaluated for
in vitro dissolution and diffusion, in addition to in vivo studies in a rat model. Loratadine nanosuspension dis-
played a particle size of 311 nm, a polydispersity index of 0.16, and zeta potential of –22.05 mV. The nano-
suspension preserved the crystalline status of the raw drug. The addition of sodium hyaluronate exhibited an
increase in the mean particle size and zeta potential of the nanoparticles. The nasal formulations showed en-
hanced bioadhesive properties compared to the unprocessed loratadine in the reference samples. The nano-
suspension based-formulation that contained 5 mg mL−1 sodium hyaluronate and 2.5 mg mL−1 loratadine (NF4)
showed a significant enhancement of flux and permeability coefficient through a synthetic membrane. NF4
exhibited 24.73 µg cm−2 h−1 and 0.082 cm h−1, while the reference sample showed 1.49 µg cm−2 h−1 and
0.017 cm h−1, for the flux and the permeability coefficient, respectively. Nasal administration of NF4 showed a
bioavailability of 5.54-fold relative to the oral administration. The results obtained in this study indicate the
potential of the nasal route and the nanosuspension for loratadine delivery. The relative bioavailability of NF4
was 1.84-fold compared to unprocessed loratadine in the reference sample. Therefore, the nanosized loratadine
could be suggested as a practical and simple nanosystem for the intranasal delivery with improved bioavail-
ability.
1. Introduction
The intranasal route has recently been introduced as an alternative
route of administration for systemic purposes rather than the delivery
of local drugs. The nasal cavity provides the advantages of large surface
area, fast absorption and rapid onset of action, and avoidance of the
first-pass metabolism. Besides, the nasal cavity is a safe and convenient
route of administration (Illum, 2003). For the systemic effect, the drug
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must be absorbed through the nasal mucosa. The absorption requires
the drug to be dissolved and permeate through the mucosal tissues to
reach the system circulation (Dhakar et al., 2011). Accordingly, poorly
soluble or/and poorly permeable drugs must be fabricated into suitable
formulations to overcome these hurdles (Costantino et al., 2007). On
the other hand, the nasal cavity shows several limitations to the in-
tranasal delivery, including short residence time, mucociliary clear-
ance, and a limited administration volume (Grassin-Delyle et al., 2012).
Solutions to resolve the mentioned limitations include using mu-
coadhesive agents to reduce mucociliary clearance and high drug
loading to handle the limited volume of administration (Musumeci
et al., 2019; Sosnik et al., 2014). Moreover, solubility and permeability
must be efficiently addressed (Ayoub et al., 2016). To enhance the
mucoadhesion, many bioadhesive agents can be added such as carbo-
mers (Bromberg, 2001), chitosans (Issa et al., 2005), thiomers (Leitner
et al., 2004), alginate (Patil and Sawant, 2009), polyethylene glycol
acrylate (Ugwoke et al., 2005) and Poloxamer (Dumortier et al., 2006;
Fonseca et al., 2014). Sodium hyaluronate (HA) is an example of the
commonly used mucoadhesive agent in nasal delivery. It extends the
contact time between the formulation and the nasal mucosa, thereby
contributing to drug absorption (Djupesland et al., 2014). On the other
hand, HA is considered biocompatible, biodegradable, and non-im-
munological material (Ding et al., 2012; Lim et al., 2000).
Drugs that belong to class II of the biopharmaceutical classification
system (BSC) show poor water-soluble and high permeable character-
istics. Therefore, dissolution is the rate-limiting step for the absorption.
Among different applied techniques, particle size reduction into the
nanorange is an effective method to produce high surface area hence
dissolution (Ambrus et al., 2019). Nanosuspensions is a well-known
approach to produce nanoparticles. Its impacts on the dissolution of
poorly water-soluble drugs have been discussed in many research stu-
dies. (Müller and Peters, 1998; Salazar et al., 2012; Yadollahi et al.,
2015).
Nanosuspensions have been introduced as a solubility enhancement
technique, and newly as a delivery system for many purposes
(Alshweiat et al., 2019a). Intranasal delivery requires the localization of
drug in the nasal cavity for sufficient time for absorption, without
dripping outside the nose or running to the throat. Therefore, nano-
particles must be incorporated into mucoadhesive formulations that
maintain the advantages of nanosizing simultaneously with localization
inside the nasal cavity.
Various studies have reported the nasal delivery of nanosuspen-
sions. Saindane et al. (2013) incorporated a carvedilol-containing na-
nosuspension into in situ gel, and Hao et al. (2016) prepared resveratrol-
based nanosuspension for brain delivery. Furthermore, meloxicam na-
nosuspension has been introduced for systemic delivery as a powder
(Kürti et al., 2013) and HA-based sprays (Bartos et al., 2015).
Loratadine (LOR) is commonly prescribed for the treatment of
various allergic conditions, mostly for seasonal allergy. LOR belongs to
class II of the BSC, and it is a weakly basic drug. Therefore, it exhibits a
pH-dependent solubility. The oral administration of LOR is associated
with variable and poor bioavailability (10–40%) (Assanasen and
Naclerio, 2002; Oppenheimer and Casale, 2002; Simons, 2002). Up to
date, the nasal dosage form is not available on the market. However,
various attempts were implemented to prepare LOR nasal form, such as
in situ nasal gel using hydroxypropylmethylcellulose (HPMC K-100) and
xanthan gum (Sherafudeen and Vasantha, 2015), β-cyclodextrin in-
clusion with Carbopol 943 and Poloxamer 407 (Rathnam et al., 2008),
and chitosan-ethylcellulose microspheres (Martinac and Filipovi,
2005).
This study aimed to develop a nasal formulation based on nano-
suspension of LOR (LNS). Size reduction could increase the dissolution
rate to obtain a higher concentration of LOR and better absorption
(Kocbek et al., 2006). In our previous work, the optimized process and
material parameters of precipitation ultrasonic-assisted method were
able to produce a pre-dispersion suitable for conversion into different
dosage forms. In the present study, LOR pre-dispersions were used to
prepare nasal formulations via the addition of sodium hyaluronate as a
mucoadhesive agent (Alshweiat et al., 2019b, 2018). To our best
knowledge, this is the first on the novel combination of nanosuspension
and nasal delivery of loratadine in the literature. The developed na-
nosystems were straightforward and scalable.
2. Materials and methods
2.1. Material
LOR was purchased from Teva Ltd. (Budapest, Hungary). Pluronic®
F68 (Poloxamer 188) was purchased from BASF (Ludwigshafen,
Germany). Ethanol was supplied by Spectrum-3D (Debrecen, Hungary).
HA (Mw = 1400 kDa) was obtained from Gedeon Richter Plc.
(Budapest, Hungary). Mucin (M), porcine gastric type- II mucin, was
purchased from Sigma Aldrich (Sigma Aldrich Co. LLC, St. Louis MO,
US). Distilled and ultra-purified water was used (Milli-Q, Millipore
GmbH, Germany).
2.2. Methods
In this study, simple methods were used to produce intranasal vis-
cous-liquid formulations based on nanosuspension. The production
process compromised the formulation of LOR nanosuspension and the
addition of the HA to the nanosuspension. The pre-dispersion and the
final formulations were characterized as follows.
2.2.1. Preparation of LOR nanosuspension
The Precipitation-ultrasonication method was used to prepare the
LNS as a pre-dispersion (Alshweiat et al., 2018). LOR was dissolved in
ethanol (200 mg mL−1) as a solvent phase, and F68 was dissolved in
water (pH 5.7) as an antisolvent phase (0.2%, w/v). Both solvent and
antisolvent phases were filtered through a 0.45 μm filter (FilterBio PES
Syringe Filter, Labex Ltd., Budapest, Hungary). The solvent phase was
rapidly introduced into the pre-cooled antisolvent under sonication
using a UP 200 s Ultrasonic processor (HielscheruUltrasonics GmbH,
Germany) for 30 min at 4 °C and 50% amplitude. The LOR:F68 in the
pre-dispersion were 2.5:1 wt ratio. The temperature of sonication was
controlled by JulaboF32 (JULABOGmbH, Germany). LNS was stirred at
room temperature for 24 h to remove the organic solvent.
2.2.2. Preparation of intranasal formulations contained LOR nanocrystals
The intranasal formulations (NFs) were prepared from the pre-dis-
persions by the addition of HA. The final concentrations of the for-
mulations were controlled by dilution with 0.2%, w/v F68. NFs were
stored in a refrigerator at 4 °C for 24 h to ensure the complete solvation
of the polymer. For comparison, reference samples (REF) were pre-
pared. Table 1 shows the final concentrations of LOR and HA in the
prepared nasal formulations and corresponding reference samples that
contained the same amount of LOR and HA in 0.2%, w/v F68. However,
the LOR in the reference samples was added without any processing.
The REF samples were prepared by mixing raw LOR powder with HA
Table 1
Concentrations of LOR and HA (mg mL−1) in nasal and reference samples.









A. Alshweiat, et al. International Journal of Pharmaceutics 579 (2020) 119166
2
and 0.2% F68 solution, using ULTRA-TURRAX® homogenizer (GmbH,
Germany) at 5000 rpm for 10 min.
2.2.3. Evaluation of the nanosuspension
The mean particle size (MPS), polydispersity index (PDI), and zeta
potential (ZP) of LNS were measured by Malvern Nano ZS zetasizer
(Malvern Instrument, UK). The samples were adequately diluted with
distilled water and measured at 25 °C and pH, 5.77. 12 parallel mea-
surements were carried out. The samples were similarly analyzed
3 days post preparation to check the stability and the size growth of the
particles.
2.2.3.1. Physicochemical characterization of the pre-dispersion. A dry
sample was obtained by drying the LNS in a vacuum dryer (Binder
GmbH, Tuttlingen, Germany) at 25 °C for 24 h to evaluate the
physicochemical properties of the nanoparticles in the pre-dispersion.
2.2.3.2. Morphology. The morphologies of LOR and the dry nanocrystal
were investigated by scanning electron microscopy (SEM) (Hitachi
S4700, Hitachi Scientific Ltd., Tokyo, Japan) at 10 kV. The samples
were coated with gold–palladium by a sputter coater (Bio-Rad SC 502,
VG Microtech, Uckfield, UK) using an electric potential of 10.0 kV at
10 mA.
2.2.3.3. X-ray powder diffraction (XRPD). The XRPD diffractograms of
LOR and the dry nanocrystals were obtained using a BRUKER D8
Advance X-ray powder diffractometer (Bruker AXS GmbH, Karlsruhe,
Germany) with Cu K λI radiation (λ = 1.5406 Å) and a VÅNTEC-1
detector. The powder samples were scanned at 40 kV and 40 mA, with
an angular range of 3°–40° 2θ, at a step time of 0.1 s and a step size of
0.01°.
2.2.3.4. Differential scanning calorimetry (DSC). The thermal analysis of
LOR and the dry nanocrystals was carried out using a differential
scanning calorimeter (Mettler Toledo DSC 821e, Mettler Inc.,
Schwerzenbach, Switzerland). 3–5 mg of the powder was accurately
weighed into DSC sample pans, which were hermetically sealed and lid
pierced. The samples were examined under constant argon purge in the
temperature interval of 25–300 °C at a heating rate of 5 °C min−1.
2.2.3.5. Fourier-transform infrared spectroscopy (FT-IR). The FTIR
spectra of LOR and the dry nanocrystals were obtained by Fourier-
transform infrared spectroscopy (Thermo Nicolet AVATAR 330, USA)
equipped with the GRAMS/AI Version seven software. Samples were
compressed into pastilles with 150 mg dry KBr. The pastilles were
scanned 128 times at a resolution of 4 cm−1 over 4000–400 cm−1
wavenumber region.
2.2.4. Characterization of HA-based nasal formulation (NF)
2.2.4.1. Determination of pH. To accurately measure the pH of the
samples, the NFs were diluted. 1 mL of the prepared NF was transferred
into a 10 mL volumetric flask. The solution was diluted with distilled
water (Sherafudeen and Vasantha, 2015). The pH of the resulting
solution was determined using a digital pH meter (Inolab, pH 7116,
Xylem Analytics Germany GmbH, Germany).
2.2.4.2. Determination of drug loading. 300 mg of NF was dissolved in
0.1 N HCl, pH 1.2. The mixture was agitated for 24 h at 37 ± 0.5 °C
and filtered. The drug content was determined using a UV–visible
spectrophotometer (Unicam UV/VIS) at ƛmax of 248 nm. Accordingly,
the percent of drug loading was calculated from the ratio of practical
and theoretical drug amount.
2.2.4.3. Rheological measurements. Rheological measurements were
performed at 37 °C with a Rheostress 1 Haake instrument (Karlsruhe,
Germany). A cone-plate device was used where the cone angle was 1°,
the thickness of the sample was 0.052 mm, and the diameter of the
device was 6 cm. The apparent viscosity curves of the samples were
plotted under the shear rate range of 0.01–100 s−1.
Rheology is one of the accepted methods to characterize mu-
coadhesive behaviors (Hassan and Gallo, 1990). Rheological synergism
between mucin and the systems can be considered as an in vitro
parameter to determine the mucoadhesive behavior of systems. This
viscosity change, called the bioadhesive viscosity component (ηb), is
caused by chemical and physical bonds formed in mucoadhesion. It can
be calculated as follows:
= − −È b È t È m È p (1)
where ƞt is the viscosity of the combination of NF with mucin, ƞm, and
ƞp are the viscosities of the mucin and NF, respectively (Hassan and
Gallo, 1990).
For mucoadhesivity, NFs were stirred with mucin (M) for 3 h before
the measurement. The final concentration of M in the samples was 5%,
w/w. The viscosity of the NFs and the combination with mucin were
measured.
2.2.4.4. In vitro studies. In vitro release was carried out in a dialysis bag
in artificial nasal fluid (ANF) media contained 8.77 mg mL−1 NaCl,
2.98 mg mL−1 KCl, and 0.59 mg mL−1 CaCl2 at pH 5.6. 300 mg of the
NF and corresponding reference were loaded into a dialysis bag and
dialyzed against 100 mL of the dissolution medium at 37 ± 0.5 °C and
under 100 rpm paddle speed. At predetermined intervals, 5 mL aliquots
were withdrawn and replaced with an equal volume of fresh dissolution
medium. The samples were filtered through a 0.45-μm filter and
analyzed by a UV spectrometer at ƛmax 248 nm.
Permeability studies were executed using a vertical Franz diffusion
cell system (Logan Instrument Carporation, NJ, USA). 300 mg of NF
was placed on the polyvinylidene fluoride synthetic membrane
(Durapore1 Membrane Filter, EMD Millipore, Billerica, MA, USA). The
membrane was impregnated with isopropyl myristate. The actual dif-
fusion surface was 1.72 cm2. Phosphate buffer (PBS, pH 7.4, 37 °C) was
used as an acceptor phase (7 mL). The rotation of the stirring bar was
set to 300 rpm. At predetermined time points of diffusion, 0.8 mL
samples were taken from the acceptor phase by the autosampler
(Hanson Microette Autosampling System, Hanson Research,
Chatsworth CA, USA) and were replaced with a fresh receiving medium.
The amount of LOR diffused was determined spectrophotometrically.
The flux (J) of the drug was calculated from the quantity of LOR that
permeated through the membrane, divided by the surface of the
membrane insert and the duration [mg cm−2 h−1] using the following
equation:
=J m/At (2)
The permeability coefficient (Kp, cm h−1) was determined from J,
and the initial concentration of the drug in the donor phase (Cd [mg
cm−3]):
=Kp[cm/h] J/Cd (3)
2.2.4.5. In vivo studies
2.2.4.5.1. Drug administration in rat’s model. The experimental
protocols and animal care methods were approved by the National
Scientific Ethical Committee on Animal Experimentation (permission
number IV/1247/2017). The animals were treated following the
European Communities Council Directives (2010/63/EU) and the
Hungarian Act for the Protection of Animals in Research (Article 32
of Act XXVIII).
A single-dose in vivo studies were designed in male Sprague-Dawley
rats weighing 220–250 g. The rats were divided into 4 groups of 4
animals each. Each rat received a dose of 0.5 mg kg−1 of LOR. For the
first group, 50–62 μL of the selected NF was administered intranasally
to each rat via a 100 μL pipette into the nostrils. For the second group,
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the rats were nasally given the corresponding REF sample. The rats
were anesthetized using 50 mg kg−1 isoflurane for 5 min before the
nasal administration.
For oral dosing, the third and fourth groups received the selected NF
sample and the corresponding REF sample, respectively. However, the
samples were mixed with distilled water to give the exact used dose in a
proper volume for oral delivery. 1 mL contained 0.5 mg kg−1 of LOR of
the samples was administered by gastric lavage.
Blood samples were collected from the tail vein. At 0.5, 1, 2, 3, 4, 8,
12, and 24 h post-dose. 0.5 mL of blood was withdrawn into Eppendorf
tubes containing sodium ethylenediaminetetraacetate. The samples
were centrifuged at 1,500 g for 10 min at 5 °C. Separated plasma
samples were stored at −80 °C until analysis.
2.2.4.5.2. Plasma sample preparation. LOR was isolated from plasma
samples by a liquid-liquid extraction procedure. To 100 µL of plasma,
10 µL ACN: H2O, (1:1, v/v), 10 µL of 3 M NaOH, and 20 µL of d5-
Loratadine (d5-LOR) − stable isotope-labeled internal standard
(15.0 ng mL−1, in ACN:H2O, 1:1, v/v) − were added. The mixture
was vortexed and shaken for 10 min at room temperature with 1 mL of
n-hexane on a horizontal shaker, then centrifuged for 10 min at
3,000 rpm at 4 °C to obtain the clear organic layer. 800 µL of the
upper organic phase was transferred into a 1.5 mL glass vial,
evaporated to dryness under a gentle stream of nitrogen and
reconstituted in 100 µL starting eluent (5 mM ammonium acetate
(pH = 5):ACN, 6:4, v/v). 20 µL was injected into the LC-MS/MS system
for analysis.
2.2.4.5.3. Preparation of the calibration curve. The calibration curve
for the quantification of LOR was set up in drug-free rat plasma. For the
preparation of standard points, 100 µL rat plasma, 10 µL LOR standard
solution (1.8–78.4 nM, diluted in ACN:H2O, 1:1, v/v), 10 µL 3 M NaOH,
and 20 µL d5-Loratadine (15.0 ng mL−1) were mixed and treated as
above.
2.2.4.6. LC-MS/MS analysis of LOR. The quantitative analysis of LOR
was performed by using a Waters Acquity I-Class UPLC™ system
(Waters, Manchester, UK), connected to a Q Exactive™ Plus Orbitrap
mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA)
equipped with a heated ESI ion source (HESI-II). Chromatographic
separation was performed at 25 °C column temperature, on an ACE CN
column (50 mm × 2.1 mm, particle size 3.0 µm) protected by an ACE
CN guard column (Advanced Chromatography Technologies, Aberdeen,
Scotland) by using 5 mM of ammonium-acetate (pH = 5) as Solvent A
and acetonitrile as Solvent B. Gradient elution program (started and
maintained at 40% B for 1 min, increased linearly to 100% B in half
min, kept at 100% B for 1.5 min, dropped back to 40% B in 0.1 min and
kept there for 1.9 min for equilibration) with a flow rate of
300 µL min−1 was applied to elute the analyte.
The mass spectrometer was used in positive mode with the fol-
lowing parameters of the HESI-II source: spray voltage at 3.5 kV, ca-
pillary temperature at 253 °C, aux gas heater temperature at 406 °C,
sheath gas flow rate at 46, aux gas flow rate at 11, and sweep gas flow
rate at 2, S-lens RF level at 50.0 (source auto-defaults). Data acquisition
was performed in parallel-reaction-monitoring (PRM) mode by mon-
itoring the transitions of m/z 383→ 337 (LOR) and m/z 388→ 342 (d5-
LOR) as quantifier and m/z 383→ 267 (LOR) and m/z 388→ 272 (d5-
LOR) as qualifier ions. The collision energy (CE) for specific quantita-
tion was optimized to maximize sensitivity and proved to be 28 eV for
LOR and its stable isotope-labelled form, too. A valve placed after the
analytical column was programmed to switch flow onto MS only when
analytes of interest elute from the column (1.4–2.4 min) to prevent
excessive contamination of the ion source and ion optics. Washing
procedures of the autosampler before and after injecting samples were
programmed to avoid carry-over of analytes.
Data acquisition and processing were carried out using Xcalibur and
Quan Browser Software (Thermo Fisher Scientific, San Jose, CA, USA).
2.2.4.7. Statistical analysis and area under the curve calculation. The
statistical analysis was performed with Prism 5.0 software (GraphPad,
San Diego, CA). The results are shown as the mean ± SD. The
statistical methods included Student's t-test (two-group comparison).
A probability (P) of less than 0.05 was considered statistically
significant (*P < 0.05).
The calculation of area under the curve (AUC) of the time (min) –
concentration (nmol L−1) curves of each group of animals were per-
formed with PKSolver add-in of Microsoft Excel (MS Office 2010) using
non-compartmental analysis of data after extravascular input (model
#101) of LOR (Zhang et al., 2010). The AUC values were calculated
using the linear trapezoidal method.
2.2.5. Stability assessment
Stability studies were carried out by visual inspection. Stable sys-
tems were identified to be free of any physical changes such as phase
separation, flocculation, or precipitation. Stability was observed at
temperatures of 4 °C and 25 °C for one month. Moreover, the for-
mulations were evaluated for particle size, polydispersity index, zeta
potential and drug content.
3. Results and discussion
3.1. Characterization of nanosuspension
The nanosuspension exhibited a MPS of 311.55 ± 5.16 nm, PDI of
0.16 ± 0.024, and ZP of –22.05 ± 2.75 mV, thus homogenous and
stable nanosuspension was produced by the antisolvent precipitation
assisted ultrasonication method. On the other hand, pure LOR showed
aggregations in the aqueous media due to its low hydrophilic properties
(Alshweiat et al., 2019b). LOR in the LNS showed saturation solubility
of 8.5 ± 0.65 μg mL−1 in PBS at pH, 5.6. Though, pure LOR showed
solubility of 1.63 ± 0.38 μg mL−1. After three days of storage, the
particles of LNS showed a MPS of 319.45 ± 4.9 nm, PDI of
0.17 ± 0.015, and ZP of −18.5 ± 4.33, respectively.
The SEM images (Fig. 1a) revealed the differences in the surface
morphology between LOR and LNS. LOR showed an irregular rod-like
crystal shape with aggregation. Conversely, LNS showed a uniform
distribution of nanoparticles within the matrix of F68.
The DSC thermograms (Fig. 1b) depict the reduction of LOR particle
size and crystallinity in LNS; LOR showed a single sharp endothermic
peak at 135 °C. The LNS showed a peak at 55 °C related to F68 and a
reduced intensity and shifted peak toward a lower melting point of
LOR.
XRPD (Fig. 1c) diffractogram of LNS and LOR were similar. There-
fore, the reduction of the melting point and intensity of LOR in the
nanocrystals sample could be related to the particle size rather than
crystallinity reduction (Murdande et al., 2015). Moreover, The FI-IR
spectra showed that LNS preserved the characteristic bands of LOR,
thus confirmed the compatibility between LOR and F68. The analysis
details and explanations are discussed in the previous related work
(Alshweiat et al., 2018).
In summary, the morphological and structural analyses have de-
monstrated that LOR was produced in the nano-range as a homogenous
nanosuspension while it preserved the crystalline state of the drug.
3.2. Characterization of the nasal formulations
The prepared NFs appeared as viscous formulations. The samples
showed drug content higher than 90%, particularly 98.98 ± 1.2,
97.66 ± 4.2, 95.15 ± 3.4, and 92.99 ± 2.8 for NF1, NF2, NF3, and
NF4, respectively. The pH of the samples was in the range of 6.3–6.4,
hence within the acceptable range for nasal administration (pH of the
nasal mucosa is 4.5–6.5) (England et al., 1999). LOR is unionized at
these pH values. Therefore, dissolution enhancement is not ascribed to
the salt form of LOR (Popovi et al., 2009).
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The addition HA had significant effects on the LOR nanosuspensions
in the NFs as the MPS, PDI, and ZP of the nanoparticles were increased.
The MPS of LOR in NF1, NF2, NF3, and NF4 was 327.2 ± 8.23,
437.2 ± 28.6, 341.6 ± 11.84, and 450.6 ± 24.3 nm, respectively.
Their respective PDI values were 0.249, 0.314, 0.254, and 0.264, re-
spectively. This significant increase in particle size could be attributed
to the coating of the particles by HA (Shen et al., 2015). Moreover, the
presence of HA in the formulation increased the negativity charge. The
ZP values were−55.1 ± 5.67,−50.3 ± 3 ± 6.68,−45.9 ± 6.36,
and −52.2 ± 6.91 mV for NF1, NF2, NF3, and NF4, respectively
(Sharma et al., 2016; Shen et al., 2015).
3.3. Rheological properties of NFs
The NFs showed a shear thinning-flow (pseudoplastic). The viscosity
curve (Fig. 2) displayed a decreasing slope, that is typical for sodium
hyaluronate solutions (Krause et al., 2001). The rheological behaviors
of the NFs were similar to the corresponding blank solutions that con-
tained 1 mg mL−1 and 5 mg mL−1 of HA in 0.2% w/v F68 noted as
blank1 and blank5, respectively. However, the reduced particle size of
LOR showed higher viscosity than the blank samples. Therefore, the
nanosized LOR improved the viscosity of blank solutions. Comparable
outcomes are reported by the work of Bartos et al. (2015).
3.4. Mucoadhesion of the nasal formulations
Samples with and without mucin were prepared to evaluate the role
of LOR nanosuspension in mucoadhesion. The bioadhesive viscosity
component, synergism parameter, was calculated from the average
viscosity values.
The systems of NFs and 5% mucin (NF-M) showed shear-thinning
behaviors. The viscosity of the NF-M systems was higher than the
corresponding NF (Suppl Fig. 1) due to the polymer or mucin en-
tanglement, and interactions between the polymer and mucin via the
hydrogen bonds (Thirawong et al., 2008).
The synergism parameters (ƞb) of the NFs were compared to the F68
solution, corresponding REF samples, and the corresponding blanks
(Fig. 3). The blanks showed mucoadhesive properties depending on the
concentration of the sodium hyaluronate. The values of the bioadhesive
viscosity were 0.6 and 46.5 mPa*s for blank1 and blank5, respectively.
The negative values ƞb of REF1 and REF3 could be related to the in-
sufficient amount of HA to interact with the mucin. The addition of the
LNS to the blanks increased the mucoadhesivity of the formulations.
This effect could be related to the interactions between the mucin and
the dispersed nanosized LOR particles.
The synergism effect was directly linked to the HA and nanosized
drug amount. These outcomes could be related to a higher interaction
Fig. 1. Raw LOR and LOR nanocrystals characterization of (a) SEM images, (b) DSC thermograms, and (c) XRPD diffractograms. The morphological and structural
analysis revealed that LOR in the nanosuspension was presented as crystalline short-rod nanocrystals.
Fig. 2. The apparent viscosity of the NFs and blank samples at 37 °C. The viscosity of the samples was reduced by increasing the shear rate (mean ± SD, n = 3).
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of the HA with the mucin and the nanocrystals. Accordingly, NF4
showed the highest synergism parameter. The ƞb was 2.8-fold com-
pared to blank5. The nanosized LOR was in the size of polymeric mo-
lecules of HA and mucin chains, hence better interaction among the
components and higher mucoadhesivity could be obtained (Horvát
et al., 2009).
NF4 that showed the highest mucoadhesive parameter. Therefore, it
was selected for further studies.
3.5. Effects of nanosizing on the diffusion and permeability of LOR
LOR shows a poor water solubility. Thus, many studies suggested
the use of 900 mL of dissolution media or/and the addition of surfactant
or co-solvent in the dissolution media to fulfill sink conditions (Damian
et al., 2016; Song and Shin, 2009; Vlaia et al., 2017). In this study, the
sink conditions were not applied due to factors related to the limited
volume of the nasal delivery, lack of surfactant on the nasal cavity to be
simulated by the dissolution media and to evaluate the effect of the
particle size reduction on dissolution and diffusion without any inter-
ventions from the surfactant. Moreover, NF4 solubility in the ANF was
6.43 ± 1.68 μg mL−1. Therefore, and based on LOR content in the
NF4, the sink conditions were not fulfilled. NF4 formulation was
compared to REF4. NF4 showed an enhanced drug release compared to
the reference sample (Fig. 4). Approximately 77% of the drug was re-
leased from NF4 within the first 15 min compared to 10% from the
reference sample. These discrepancies in dissolution rates could be re-
lated to the nanosizing effects, as small particles produced a higher
surface area than the microparticles. Thus, dissolution according to the
Noys-Whitney equation. Moreover, the nanosizing of LOR showed a
5.2-fold saturation solubility compared to the raw drug (Agrawal and
Patel, 2011).
The diffusion indicates the permeation property. In this study, the
membrane pore size was 100 nm, so LOR particles were unable to pass
directly through the membrane. Consequently, the high surface area
achieved by the nanosized particles was the main factor affecting the
rate of passive diffusion.
The diffusion from NF4 was faster than REF4 due to the higher
dissolution of the drug (Fig. 5). LOR diffused immediately from NF4
while is diffused after 10 min from the REF4. The flux (J) represents the
amount of LOR permeated through a 1 cm2 of the membrane within 1 h.
NF4 that contained LOR nanoparticles showed a significantly increased
J compared to REF4 (24.73 ± 3.2 and 1.49 ± 1.03 µg cm−2 h−1,
respectively). Therefore, HA containing-formulations allowed the pe-
netration of LOR through the synthetic membrane. However, the flux of
the nanosized-based formulation was higher than the reference sample
containing the raw LOR. The permeability coefficient (Kp) of NF4 also
showed a higher value than REF4. Kp values were 0.082 and
0.017 cm h−1, respectively. In particular, 11.15 µg cm−2 of the drug
diffused in the first 15 min from the NF4 compared to 0.56 µg cm−2
form the REF4. The higher diffusion could be connected to the higher
Fig. 3. Calculated synergism parameters at a shear rate of 100 s−1 and 37 °C. The nanosized formulation showed higher viscosity parameter than the corresponding
REF samples and blank solutions (mean ± SD, n = 3).
Fig. 4. Dissolution profile of NF4 and REF4 in ANF media at 37 °C. NF4 showed higher dissolution compared to the release from REF4 that contained unprocessed
LOR (mean ± SD, n = 3).
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surface area produced by the nanoparticles. The viscosity of the NF4
was at a low level (Section 3.3) that is suitable for nasal spray (Bartos
et al., 2018).
3.6. In vivo studies
Nanosuspension based LOR was designed to improve the drug
bioavailability by the intranasal route. Plasma levels after intranasal
administration of the nanoparticle formulations were compared with
those achieved with a reference sample that contained unprocessed
suspended LOR (REF4). Moreover, nasal delivery was compared to the
oral one. Fig. 6 shows the mean LOR plasma concentration-time profiles
after intranasal and oral delivery of NF4 and REF4.
As stated previously, LOR belongs to class II of the BCS. Thus it
shows good permeability. Cmax after the nasal administration is sig-
nificantly higher than the oral administration (P≤ 0.01). The Cmax was
6.388, 13.29, 38.357, and 39.991 nM for REF4-oral, NF4-oral, REF4-
nasal, and NF4-nasal, respectively (Table 2). The higher nasal con-
centrations could be related to higher absorption through the high
vascularized mucosa and bypassing the first-pass metabolism. More-
over, HA could act as a permeation enhancer for LOR through the nasal
mucosa (Illum et al., 1994). Apart from this, the plasma concentration
of REF4-oral, REF4-nasal, and NF4-oral decreased after 12 h. However,
NF4-nasal plasma concentration was 3.85 nmol L−1 and still detected to
24 h resulting in lower ke.
The mucoadhesive properties for the nanosuspension in NF4 were
visible as mucoadhesion would improve the drug absorption and could
prolong the intimate contact time of the particle on the nasal mucosa by
adhering to the surface of the mucus layer. Therefore, NF4 showed
extended and elevated plasma concentration of LOR than REF4, con-
sidering the exclusion of the mucoadhesive agent consequences as the
samples contained the same concentrations of HA (Morimoto et al.,
1991). Fig. 7 shows the AUC 0- ∞ values (Table 2) for LOR after oral and
nasal administration. The relative bioavailability of the intranasal de-
livered NF4 was 1.84-fold compared to the REF4 and 5.54-fold com-
pared to the oral delivered sample i.e. NF4-oral.
These findings provide evidence that nasal administration enhanced
the bioavailability of LOR. Moreover, the nanoparticles are practical to
improve the delivery of LOR through the nasal route.
3.7. Stability
There was no significant change in terms of physical appearance
and viscosity. Furthermore, no particle precipitation occurred over one
month for the samples kept at 4 °C. Though, the samples at 25 °C
showed precipitation and phase separation. Thus, the storage of for-
mulations would be more appropriate at refrigerated conditions to
ensure the stability of the products. The drug content of NF4 samples
after the storage period at 4 °C was 89.48 ± 3.6%.
The mean particle size of LOR nanoparticles in NF4 was
395.1 ± 11.13. Moreover, the NF4 showed a PDI of 0.35 ± 0.02 and
ZP of –39.4 ± 6.84. The stability of the formulation could be related to
Fig. 5. In vitro permeability of NF4 and REF4 through a synthetic membrane using a Franz-diffusion cell at 37 °C. NF4 showed a higher flux and permeability of LOR
than REF4 (mean ± SD, n = 3).
Fig. 6. Plasma concentration of LOR (nmol L−1) after nasal and oral delivery of NF4 and REF4 samples. The intranasal delivery showed higher plasma concentrations
than oral administration and the nanosuspension based formulation showed higher plasma concentration than REF4 (mean ± SD, n = 4).
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the high zeta potential and the viscosity of the formulation that kept the
LOR nanoparticles separated and homogeneously distributed through
the matrix (Müller and Jacobs, 2002). Moreover, the reduction of
particle size after 1-month storage compared to the fresh samples could
be related to the drug-stabilizer interactions (Md et al., 2018).
4. Conclusions
Simple methods of preparation were used to develop loratadine
nasal formulation. The combination of nanosuspension and simple ad-
dition of a mucoadhesive agent presented a promising platform for the
nasal delivery of loratadine. The crystalline state of LOR was not altered
through nanosizing by the ultrasonication method. Thus, long-term
time stability of formulations could be improved. The reduction of
particle size presented enhanced mucoadhesive properties. Moreover,
using a mucoadhesive agent is crucial to extend the contact time be-
tween the formulation and nasal mucosa. The parameters of polymer
concentration, drug concentration, and interaction with mucin were
studied. More precisely, NF4 formulation that contained 2.5 mg mL−1
of loratadine and 5 mg mL−1 sodium hyaluronate showed enhanced
rheological behaviors as presented by the synergism parameter where
nanosizing had the main effect in the higher mucoadhesivity. Moreover,
NF4 showed enhanced dissolution in an artificial nasal fluid. Besides,
higher diffusion and permeability coefficient compared to the un-
processed loratadine. The evidence from the in vivo studies showed the
superiority of nasal delivery over the oral administration.
CRediT authorship contribution statement
Areen Alshweiat: Conceptualization, Methodology, Investigation,
Formal analysis. IIdikó Csóka: Supervision. Ferenc Tömösi:
Methodology. Tamás Janáky: Supervision. Anita Kovács:
Investigation. Róbert Gáspár: Data curation. Anita Sztojkov-Ivanov:
Investigation. Eszter Ducza: Methodology. Árpád Márki: Data cura-
tion. Piroska Szabó-Révész: Supervision. Rita Ambrus: Supervision,
Project administration, Resources, Writing - review & editing.
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Acknowledgments
This work was supported by Gedeon Richter Ltd – GINOP project
(2.2.1-15-2016-00007), Ministry of Human Capacities, Hungary grant
20391-3/2018/FEKUSTRAT and TUDFO/47138-1/2019-ITM project is
also acknowledged.
Appendix A. Supplementary material
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ijpharm.2020.119166.
References
Agrawal, Y., Patel, V., 2011. Nanosuspension: An approach to enhance solubility of drugs.
J. Adv. Pharm. Technol. Res. 2, 81. https://doi.org/10.4103/2231-4040.82950.
Alshweiat, A., Ambrus, R., Csoka, I., 2019a. Intranasal nanoparticulate systems as alter-
native route of drug delivery. Curr. Med. Chem. 26, 6459–6492. https://doi.org/10.
2174/0929867326666190827151741.
Alshweiat, A., Ambrus, R., Katona, G., Csoka, Ii, 2019b. QbD based control strategy of
loratadine nanosuspensions and dry nanoparticles stabilized by soluplus®. Farmacia
67, 729–735. https://doi.org/10.31925/farmacia.2019.4.23.
Alshweiat, A., Katona, G., Csóka, I., Ambrus, R., 2018. Design and characterization of
loratadine nanosuspension prepared by ultrasonic-assisted precipitation. Eur. J.
Pharm. Sci. 122, 94–104. https://doi.org/10.1016/j.ejps.2018.06.010.
Ambrus, R., Alshweiat, A., Csóka, I., Ovari, G., Esmail, A., Radacsi, N., 2019. 3D-printed
electrospinning setup for the preparation of loratadine nanofibers with enhanced
physicochemical properties. 118455. Int. J. Pharm. 567. https://doi.org/10.1016/j.
ijpharm. 2019. 118455.
Assanasen, P., Naclerio, R.M., 2002. Antiallergic anti-inflammatory effects of H1-anti-
histamines in humans. Clin. Allergy Immunol. 17, 101–139.
Ayoub, A.M., Ibrahim, M.M., Abdallah, M.H., Mahdy, M.A., 2016. Sulpiride microemul-
sions as antipsychotic nasal drug delivery systems: In-vitro and pharmacodynamic
study. J. Drug Deliv. Sci. Technol. 36, 10–22. https://doi.org/10.1016/j.jddst.2016.
09.002.
Bartos, C., Ambrus, R., Kovács, A., Gáspár, R., Sztojkov-Ivanov, A., Márki, Á., Janáky, T.,
Tmsi, F., Kecskeméti, G., Szabó-Révész, P., 2018. Investigation of absorption routes of
meloxicam and its salt form from intranasal delivery systems. Molecules 23, 1–13.
https://doi.org/10.3390/molecules23040784.
Bartos, C., Ambrus, R., Sipos, P., Budai-Szucs, M., Csányi, E., Gáspár, R., Márki, Á., Seres,
A.B., Sztojkov-Ivanov, A., Horváth, T., Szabó-Révész, P., 2015. Study of sodium
hyaluronate-based intranasal formulations containing micro- or nanosized melox-
icam particles. Int. J. Pharm. 491, 198–207. https://doi.org/10.1016/j.ijpharm.
2015.06.046.
Bromberg, L.E., 2001. Enhanced nasal retention of hydrophobically modified polyelec-
trolytes. J. Pharm. Pharmacol. 53, 109–114. https://doi.org/10.1211/
0022357011775082.
Costantino, H.R., Illum, L., Brandt, G., Johnson, P.H., Quay, S.C., 2007. Intranasal de-
livery: Physicochemical and therapeutic aspects. Int. J. Pharm. 337, 1–24. https://
doi.org/10.1016/j.ijpharm.2007.03.025.
Damian, F., Harati, M., Pathak, V., Schwartzenhauer, J., Durham, D., Quiquero, V., Van
Cauwenberghe, O., Wettig, S.D., 2016. Development of a discriminating dissolution
method for immediate-release soft gelatin capsules containing a BCS class II com-
pound. Dissolution Technol. 23, 6–13. https://doi.org/10.14227/DT230416P6.
Dhakar, R.C., Maurya, S.D., Tilak, V.K., Gupta, A.K., 2011. A review on factors affecting
the design of nasal drug delivery system. Int. J. Drug Deliv. 1, 194–208.
Ding, J., He, R., Zhou, G., Tang, C., Yin, C., 2012. Multilayered mucoadhesive hydrogel
films based on thiolated hyaluronic acid and polyvinylalcohol for insulin delivery.
Acta Biomater. 8, 3643–3651. https://doi.org/10.1016/j.actbio.2012.06.027.
Djupesland, P.G., Messina, J.C., Mahmoud, R.A., 2014. Therapeutic Delivery 5, 709–733.
Dumortier, G., Grossiord, J.L., Agnely, F., Chaumeil, J.C., 2006. A review of poloxamer
Table 2
Pharmacokinetics parameters of LOR concentration in plasma after administration of NF4 and REF4 using oral and intranasal administration (Mean ± SD, n = 4).
Oral Intranasal
NF4 REF4 NF4 REF4
ke [h−1] 0.240 ± 0.036 0.238 ± 0.034 0.115 ± 0.013 0.236 ± 0.085
Cmax [nM] 13.29 ± 5.716 6.388 ± 2.205 39.991 ± 14.180 38.357 ± 9.778
AUC0-∞ [h nmol L−1] 36.588 ± 9.785 17.812 ± 1.962 202.708 ± 43.311 110.353 ± 10.414
Fig. 7. AUC 0– ∞ (h nmol L−1) of plasma after nasal and oral administration of
NF4 and REF4. The nasal delivery NF4 showed an improved bioavailability
compared to the REF4 and to oral administration (*, P = 0.02; **, P = 0.003,
***, P = 0.0003) (mean ± SD, n = 4).
A. Alshweiat, et al. International Journal of Pharmaceutics 579 (2020) 119166
8
407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23,
2709–2728. https://doi.org/10.1007/s11095-006-9104-4.
England, R.J.A., Homer, J.J., Knight, L.C., Ell, S.R., 1999. Nasal pH measurement: A re-
liable and repeatable parameter. Clin. Otolaryngol. Allied Sci. 24, 67–68. https://doi.
org/10.1046/j.1365-2273.1999.00223.x.
Fonseca, F.N., Betti, A.H., Carvalho, F.C., Gremião, M.P.D., Dimer, F.A., Guterres, S.S.,
Tebaldi, M.L., Rates, S.M.K., Pohlmann, A.R., 2014. Mucoadhesive amphiphilic me-
thacrylic copolymer-functionalized poly(ε-caprolactone) nanocapsules for nose-to-
brain delivery of olanzapine. J. Biomed. Nanotechnol. 11, 1472–1481. https://doi.
org/10.1166/jbn.2015.2078.
Grassin-Delyle, S., Buenestado, A., Naline, E., Faisy, C., Blouquit-Laye, S., Couderc, L.J.,
Le Guen, M., Fischler, M., Devillier, P., 2012. Intranasal drug delivery: An efficient
and non-invasive route for systemic administration - Focus on opioids. Pharmacol.
Ther. 134, 366–379. https://doi.org/10.1016/j.pharmthera.2012.03.003.
Hao, J., Zhao, J., Zhang, S., Tong, T., Zhuang, Q., Jin, K., Chen, W., Tang, H., 2016.
Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions
intended for direct nose-to-brain delivery. Colloids Surf., B: Biointerfaces. 147,
376–386. https://doi.org/10.1016/j.colsurfb.2016.08.011.
Hassan, E.E., Gallo, J.M., 1990. A simple rheological method for the in vitro assessment of
mucin-polymer bioadhesive bond strength. Pharm. Res.: Pharm. Res. 7, 491–495.
https://doi.org/10.1023/A:1015812615635.
Horvát, S., Fehér, A., Wolburg, H., Sipos, P., Veszelka, S., Tóth, A., Kis, L., Kurunczi, A.,
Balogh, G., Kürti, L., Eros, I., Szabó-Révész, P., Deli, M.A., 2009. Sodium hyaluronate
as a mucoadhesive component in nasal formulation enhances delivery of molecules to
brain tissue. Eur. J. Pharm. Biopharm. 72, 252–259. https://doi.org/10.1016/j.ejpb.
2008.10.009.
Illum, L., 2003. Nasal drug delivery — possibilities, problems and solutions. J. Control.
Release. 7, 187–198. https://doi.org/10.1016/S0168-3659(02)00363-2.
Illum, L., Farraj, N.F., Fisher, A.N., Gill, I., Miglietta, M., Benedetti, L.M., 1994.
Hyaluronic acid ester microspheres as a nasal delivery system for insulin. J. Control.
Release. 29, 133–141. https://doi.org/10.1016/0168-3659(94)90129-5.
Issa, M.M., Köping-Höggård, M., Artursson, P., 2005. Chitosan and the mucosal delivery
of biotechnology drugs. Drug Discov. Today Technol. 2, 1–6. https://doi.org/10.
1016/j.ddtec.2005.05.008.
Kocbek, P., Baumgartner, S., Kristl, J., 2006. Preparation and evaluation of nanosus-
pensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 312,
179–186. https://doi.org/10.1016/j.ijpharm.2006.01.008.
Krause, W.E., Bellomo, E.G., Colby, R.H., 2001. Rheology of sodium hyaluronate under
physiological conditions. Biomacromolecules 2, 65–69. https://doi.org/10.1021/
bm0055798.
Kürti, L., Gáspár, R., Márki, Á., Kápolna, E., Bocsik, A., Veszelka, S., Bartos, C., Ambrus,
R., Vastag, M., Deli, M.A., Szabó-Révész, P., 2013. In vitro and in vivo character-
ization of meloxicam nanoparticles designed for nasal administration. Eur. J. Pharm.
50, 86–92. https://doi.org/10.1016/j.ejps.2013.03.012.
Leitner, V.M., Guggi, D., Krauland, A.H., Bernkop-Schnärch, A., 2004. Nasal delivery of
human growth hormone: In vitro and in vivo evaluation of a thiomer/glutathione
microparticulate delivery system. J. Control. Release. 100, 87–95. https://doi.org/
10.1016/j.jconrel.2004.08.001.
Lim, S.T., Martin, G.P., Berry, D.J., Brown, M.B., 2000. Preparation and evaluation of the
in vitro drug release properties and mucoadhesion of novel microspheres of hya-
luronic acid and chitosan. J. Control. Release. 66, 281–292. https://doi.org/10.1016/
S0168-3659(99)00285-0.
Martinac, A., Filipovi, J., 2005. Development and bioadhesive properties of chitosan-
ethylcellulose microspheres for nasal delivery. Int. J. Pharm. 291, 69–77. https://doi.
org/10.1016/j.ijpharm.2004.07.044.
Md, S., Kit, B.C.M., Jagdish, S., David, D.J.P., Pandey, M., Chatterjee, L.A., 2018.
Development and in vitro evaluation of a zerumbone loaded nanosuspension drug
delivery system. Crystals 8, 1–13. https://doi.org/10.3390/cryst8070286.
Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi, Y., Nakai, Y., 1991.
Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vaso-
pressin and an analogue. Pharm. Res. 8, 471–474. https://doi.org/10.1023/
a:1015894910416.
Müller, R.H., Jacobs, C., 2002. Buparvaquone mucoadhesive nanosuspension: prepara-
tion, optimisation and long-term stability. Int. J. Pharm. 237, 151–161. https://doi.
org/10.1016/S0378-5173(02)00040-6.
Müller, R.H., Peters, K., 1998. Nanosuspensions for the formulation of poorly soluble
drugs. I. Preparation by a size-reduction technique. Int. J. Pharm. 160, 229–237.
https://doi.org/10.1016/S0378-5173(97)00311-6.
Murdande, S.B., Shah, D.A., Dave, R.H., 2015. Impact of nanosizing on solubility and
dissolution rate of poorly soluble impact of nanosizing on solubility and dissolution
rate of poorly. J. Pharm. Sci. 104, 2094–2102. https://doi.org/10.1002/jps.24426.
Musumeci, T., Bonaccorso, A., Puglisi, G., 2019. Epilepsy disease and nose-to-brain de-
livery of polymeric nanoparticles: an overview. Pharmaceutics 11, 118. https://doi.
org/10.3390/pharmaceutics11030118.
Oppenheimer, J.J., Casale, T.B., 2002. Next generation antihistamines: therapeutic ra-
tionale, accomplishments and advances. Expert Opin. Investig. Drugs. 11, 807–817.
https://doi.org/10.1517/13543784.11.6.807.
Patil, S.B., Sawant, K.K., 2009. Development, optimization and in vitro evaluation of
alginate mucoadhesive microspheres of carvedilol for nasal delivery. J.
Microencapsul. 26, 432–443. https://doi.org/10.1080/02652040802456726.
Popovi, G., ˇCakar, M., Agbaba, D., 2009. Acid – base equilibria and solubility of lor-
atadine and desloratadine in water and micellar media. J. Pharm. Biomed. Anal. 49,
42–47. https://doi.org/10.1016/j.jpba.2008.09.043.
Rathnam, G., Narayanan, N., Ilavarasan, R., 2008. Carbopol-based gels for nasal delivery
of progesterone. AAPS. PharmSciTech. 9, 1078–1082. https://doi.org/10.1208/
s12249-008-9144-7.
Saindane, N.S., Pagar, K.P., Vavia, P.R., 2013. Nanosuspension based in situ gelling nasal
spray of carvedilol: development, in vitro and in vivo characterization. AAPS.
PharmSciTech. 14, 189–199. https://doi.org/10.1208/s12249-012-9896-y.
Salazar, J., Ghanem, A., Müller, R.H., Möschwitzer, J.P., 2012. Nanocrystals: Comparison
of the size reduction effectiveness of a novel combinative method with conventional
top-down approaches. Eur. J. Pharm. Biopharm. 81, 82–90. https://doi.org/10.1016/
j.ejpb.2011.12.015.
Sharma, S., Singh, J., Verma, A., Teja, B.V., Shukla, R.P., Singh, S.K., Sharma, V., Konwar,
R., Mishra, P.R., 2016. Hyaluronic acid anchored paclitaxel nanocrystals improves
chemotherapeutic efficacy and inhibits lung metastasis in tumor-bearing rat model.
RSC Adv. 6, 73083–73095. https://doi.org/10.1039/C6RA11260A.
Shen, H., Shi, S., Zhang, Z., Gong, T., Sun, X., 2015. Coating solid lipid nanoparticles with
hyaluronic acid enhances antitumor activity against melanoma stem-like cells.
Theranostics 5, 755–771. https://doi.org/10.7150/thno.10804.
Sherafudeen, S.P., Vasantha, P.V., 2015. Development and evaluation of in situ nasal gel
formulations of loratadine. Res. Pharm. Sci. 10, 466–476.
Simons, F.E.R., 2002. Comparative pharmacology of H1 antihistamines: clinical re-
levance. N. Engl. J. Med. 113 (Suppl), 38S–46S. https://doi.org/10.1016/S0002-
9343(02)01436-5.
Song, J.H., Shin, S.C., 2009. Development of the loratadine gel for enhanced transdermal
delivery. Drug Dev. Ind. Pharm. 35, 897–903. https://doi.org/10.1080/
03639040802680289.
Sosnik, A., Das Neves, J., Sarmento, B., 2014. Mucoadhesive polymers in the design of
nano-drug delivery systems for administration by non-parenteral routes: A review.
Prog. Polym. Sci. 39, 2030–2075. https://doi.org/10.1016/j.progpolymsci.2014.07.
010.
Thirawong, N., Kennedy, R.A., Sriamornsak, P., 2008. Viscometric study of pectin-mucin
interaction and its mucoadhesive bond strength. Carbohydr. Polym. 71, 170–179.
https://doi.org/10.1016/j.carbpol.2007.05.026.
Ugwoke, M.I., Agu, R.U., Verbeke, N., Kinget, R., 2005. Nasal mucoadhesive drug de-
livery: Background, applications, trends and future perspectives. Adv. Drug Deliv.
Rev. 57, 1640–1665. https://doi.org/10.1016/j.addr.2005.07.009.
Vlaia, L., Coneac, G., Olariu, I., Lupuliasa, T., Dan, A.M., Maxim, M.E., Saramet, G., Mitu,
M., Lupuliasa, D., Vlaia, V., 2017. Loratadine-loaded microemulsions for topical
application. Formulation, physicochemical characterization and in vitro drug release
evaluation. Farmacia 65, 851–861.
Yadollahi, R., Vasilev, K., Simovic, S., 2015. Nanosuspension technologies for delivery of
poorly soluble drugs - A review. J. Nanomater. 15, 1–13. https://doi.org/10.1155/
2015/216375.
Zhang, Y., Huo, M., Zhou, J., Xie, S., 2010. PKSolver: An add-in program for pharma-
cokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods.
Programs. Biomed. 99, 306–314. https://doi.org/10.1016/j.cmpb.2010.01.007.
A. Alshweiat, et al. International Journal of Pharmaceutics 579 (2020) 119166
9
